All Updates

All Updates

icon
Filter
Funding
Universal DX raises funding in Series B funding to support the clinical trial of its colorectal cancer screening blood test, Signal-C
Precision Medicine
Aug 16, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Precision Medicine

Precision Medicine

Aug 16, 2024

Universal DX raises funding in Series B funding to support the clinical trial of its colorectal cancer screening blood test, Signal-C

Funding

  • Universal DX has concluded its Series B funding round. The amount raised was not disclosed, but noted investors involved include Quest Diagnostics and newcomers such as Olympus Innovation Ventures.

  • The funds will be used to continue the clinical trial of UDX's colorectal cancer screening blood test, Signal-C. The company initiated patient enrollment in January 2024 and aims to obtain premarket approval from the US FDA for Signal-C. UDX anticipates recruiting at least 15,000 participants across 100 sites for the Signal-C trial.

  • Analyst QuickTake: Prior to this, in November 2023, Universal DX raised USD 70 million in a Series B funding round , with participation from genetic testing company Quest Diagnostics, which was expected to be exclusively offering UDX's Signal-C colorectal cancer screening test in the US via a strategic partnership between the two firms.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.